Targeting the mTOR pathway using deforolimus in cancer therapy.
about
Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous miceNew developments in mammalian target of rapamycin inhibitors for the treatment of sarcomaA single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.6"-Debromohamacanthin A, a bis (indole) alkaloid, inhibits angiogenesis by targeting the VEGFR2-mediated PI3K/AKT/mTOR signaling pathways.Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways.Repression of glucocorticoid-stimulated angiopoietin-like 4 gene transcription by insulin.Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway.Aging and TOR: interwoven in the fabric of life.Role of mTOR signaling in tumor cell motility, invasion and metastasisAging and cancer: can mTOR inhibitors kill two birds with one drug?PTEN loss in the continuum of common cancers, rare syndromes and mouse models.Mammalian target of rapamycin as a target in hematological malignancies.Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.Metformin and Prostate Cancer: a New Role for an Old Drug.Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma.Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside.
P2860
Q24597354-BF2F7E9C-5FFF-44D5-B66A-08567617EAD6Q36144084-29C374D5-3D87-47A0-81CD-C4C08082F4D8Q36275411-21DF0B66-7649-4536-BDB6-92043D9F45B2Q36994218-2FA620EA-8E62-44B4-8B06-E091E640165DQ37093269-DF6CF3B2-7499-404F-A536-225DBA706BE4Q37364509-DCCAFD57-4867-480B-ADD7-D5120C39CEDDQ37716367-53F8BFB5-D81C-48C4-9425-A7AABD5147F4Q37775890-45CE15BD-074B-4DC4-B0FC-C535950F756CQ37801565-1471A829-DDC3-4413-A006-68708B5BBC3CQ37824477-51A915B7-B778-4902-BC59-AF5309E08AD9Q37851872-3E4FE460-DA7A-492F-AD80-0F1A27883A05Q37856722-8B31D3FF-A00E-44BC-A0DA-016D271C5E5DQ37866136-FAF946AC-D396-49E9-B633-BA880088B609Q38131047-17DEC109-46E0-4506-9325-4F431FA5AD83Q38819039-651DF151-A8EB-4817-949E-F511CF833691Q39184115-AB48F812-3F34-4EE1-8C5B-8F70726535A5Q39414806-29AD8B72-9FAB-472A-AC30-B6789C4D56AEQ41866875-DBE88723-CFB6-4B2A-AC16-09A757D314A2Q45743838-4E5E1CC7-062F-48EA-A7E3-6CAAAEC15878
P2860
Targeting the mTOR pathway using deforolimus in cancer therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting the mTOR pathway using deforolimus in cancer therapy.
@en
Targeting the mTOR pathway using deforolimus in cancer therapy.
@nl
type
label
Targeting the mTOR pathway using deforolimus in cancer therapy.
@en
Targeting the mTOR pathway using deforolimus in cancer therapy.
@nl
prefLabel
Targeting the mTOR pathway using deforolimus in cancer therapy.
@en
Targeting the mTOR pathway using deforolimus in cancer therapy.
@nl
P2093
P2860
P356
P1433
P1476
Targeting the mTOR pathway using deforolimus in cancer therapy.
@en
P2093
Alain Mita
Devalingam Mahalingam
Francis J Giles
Kamalesh Sankhala
Monica M Mita
P2860
P304
P356
10.2217/FON.09.9
P407
P577
2009-04-01T00:00:00Z